$SGMO
Sangamo Therapeutics Inc

2014 Q2 Form 10-Q Financial Statement

#000119312514187386 Filed on May 07, 2014

View on sec.gov

Income Statement

Concept 2014 Q2 2014 Q1 2013 Q1
Revenue $10.39M $8.116M $4.623M
YoY Change 49.77% 75.56% 42.55%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.970M $3.640M $3.310M
YoY Change 27.24% 9.97% 2.16%
% of Gross Profit
Research & Development $13.46M $12.08M $8.220M
YoY Change 45.07% 47.0% 12.91%
% of Gross Profit
Depreciation & Amortization $200.0K $123.0K $147.0K
YoY Change 0.0% -16.33% -26.5%
% of Gross Profit
Operating Expenses $17.43M $15.73M $11.53M
YoY Change 40.56% 36.42% 9.52%
Operating Profit -$7.611M -$6.905M
YoY Change 10.22%
Interest Expense $70.00K $40.00K $20.00K
YoY Change 250.0% 100.0% 0.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$6.980M -$7.572M -$6.890M
YoY Change 28.07% 9.9% -5.23%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$6.981M -$7.572M -$6.885M
YoY Change 28.09% 9.98% -5.27%
Net Earnings / Revenue -67.22% -93.3% -148.93%
Basic Earnings Per Share
Diluted Earnings Per Share -$102.7K -$119.8K -$129.1K
COMMON SHARES
Basic Shares Outstanding 67.96M shares 62.74M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q2 2014 Q1 2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $193.7M $213.4M $57.30M
YoY Change 309.51% 272.43% -28.11%
Cash & Equivalents $99.27M $126.8M $12.18M
Short-Term Investments $94.40M $86.60M $45.10M
Other Short-Term Assets $671.0K $349.0K $300.0K
YoY Change -48.38% 16.33% 0.0%
Inventory
Prepaid Expenses $1.053M $370.0K
Receivables $6.969M $5.360M $3.700M
Other Receivables $300.0K $300.0K $200.0K
Total Short-Term Assets $203.0M $220.2M $61.50M
YoY Change 277.99% 258.07% -24.82%
LONG-TERM ASSETS
Property, Plant & Equipment $1.622M $1.410M $1.500M
YoY Change 1.38% -6.0% -11.76%
Goodwill $1.585M $1.585M
YoY Change
Intangibles
YoY Change
Long-Term Investments $42.70M $30.40M $12.80M
YoY Change 127.13% 137.5% 85.51%
Other Assets $0.00 $0.00 $0.00
YoY Change
Total Long-Term Assets $47.86M $35.29M $14.30M
YoY Change 133.45% 146.77% 66.28%
TOTAL ASSETS
Total Short-Term Assets $203.0M $220.2M $61.50M
Total Long-Term Assets $47.86M $35.29M $14.30M
Total Assets $250.8M $255.5M $75.80M
YoY Change 238.06% 237.07% -16.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.700M $6.100M $2.500M
YoY Change 72.73% 144.0% 4.17%
Accrued Expenses $2.000M $1.500M $1.100M
YoY Change 42.86% 36.36% 10.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $16.80M $16.41M $6.000M
YoY Change 136.61% 173.43% 7.14%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $18.90M $20.90M $8.300M
YoY Change 142.31% 151.81% -20.95%
Total Long-Term Liabilities $18.90M $20.90M $8.300M
YoY Change 142.31% 151.81% -20.95%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.80M $16.41M $6.000M
Total Long-Term Liabilities $18.90M $20.90M $8.300M
Total Liabilities $36.48M $38.08M $14.30M
YoY Change 146.49% 166.26% -11.18%
SHAREHOLDERS EQUITY
Retained Earnings -$316.7M -$309.7M
YoY Change
Common Stock $681.0K $678.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $214.4M $217.4M $61.60M
YoY Change
Total Liabilities & Shareholders Equity $250.8M $255.5M $75.80M
YoY Change 238.06% 237.07% -16.15%

Cashflow Statement

Concept 2014 Q2 2014 Q1 2013 Q1
OPERATING ACTIVITIES
Net Income -$6.981M -$7.572M -$6.885M
YoY Change 28.09% 9.98% -5.27%
Depreciation, Depletion And Amortization $200.0K $123.0K $147.0K
YoY Change 0.0% -16.33% -26.5%
Cash From Operating Activities -$8.600M $11.38M -$8.018M
YoY Change 62.26% -241.92% -376.48%
INVESTING ACTIVITIES
Capital Expenditures -$400.0K $126.0K $68.00K
YoY Change 100.0% 85.29% -134.0%
Acquisitions
YoY Change
Other Investing Activities -$20.40M $4.000M -$3.700M
YoY Change -666.67% -208.11% -174.0%
Cash From Investing Activities -$20.80M $3.887M -$3.731M
YoY Change -750.0% -204.18% -179.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $7.585M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.700M 101.4M 2.247M
YoY Change -10.53% 4411.39% 2147.0%
NET CHANGE
Cash From Operating Activities -8.600M 11.38M -8.018M
Cash From Investing Activities -20.80M 3.887M -3.731M
Cash From Financing Activities 1.700M 101.4M 2.247M
Net Change In Cash -27.70M 116.6M -9.502M
YoY Change 13750.0% -1327.5% -223.4%
FREE CASH FLOW
Cash From Operating Activities -$8.600M $11.38M -$8.018M
Capital Expenditures -$400.0K $126.0K $68.00K
Free Cash Flow -$8.200M $11.25M -$8.086M
YoY Change 60.78% -239.17% -360.84%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
67959769 shares
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12177000
CY2014Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
67822302 shares
CY2014Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
67822302 shares
CY2014Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2014Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2014Q1 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
1620000
CY2014Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6112000
CY2014Q1 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
748000
CY2014Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
526431000
CY2014Q1 us-gaap Liabilities Current
LiabilitiesCurrent
16406000
CY2014Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
21000
CY2014Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1620000
CY2014Q1 us-gaap Stockholders Equity
StockholdersEquity
217425000
CY2014Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1471000
CY2014Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5360000
CY2014Q1 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1870000
CY2014Q1 us-gaap Other Assets
OtherAssets
39000
CY2014Q1 us-gaap Other Assets Current
OtherAssetsCurrent
349000
CY2014Q1 us-gaap Interest Receivable Current
InterestReceivableCurrent
383000
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
748000
CY2014Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-309705000
CY2014Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
8548000
CY2014Q1 us-gaap Common Stock Value
CommonStockValue
678000
CY2014Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
255500000
CY2014Q1 us-gaap Liabilities
Liabilities
38075000
CY2014Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
19301000
CY2014Q1 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
1620000
CY2014Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
86607000
CY2014Q1 us-gaap Assets Current
AssetsCurrent
220212000
CY2014Q1 us-gaap Goodwill
Goodwill
1585000
CY2014Q1 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
30384000
CY2014Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
320000
CY2014Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
370000
CY2014Q1 us-gaap Assets
Assets
255500000
CY2014Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
124225000
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
126823000
CY2014Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1410000
CY2014Q1 sgmo Escrow Liability
EscrowLiability
275000
CY2014Q1 sgmo Investments Maturity Dates Available For Sale Securities
InvestmentsMaturityDatesAvailableForSaleSecurities
P1Y
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21679000
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
62243892 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
62243892 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
423209000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10131000
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
12000
CY2013Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1570000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
121710000
CY2013Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
3194000
CY2013Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
1570000
CY2013Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4380000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-302133000
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2282000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
622000
CY2013Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-61000
CY2013Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8661061 shares
CY2013Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6886000
CY2013Q1 us-gaap Revenues
Revenues
4623000
CY2013Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
16573000
CY2013Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
20000
CY2013Q1 us-gaap Revenue From Grants
RevenueFromGrants
540000
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6905000
CY2013Q1 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
68000
CY2013Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-546000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
140838000
CY2013Q4 us-gaap Liabilities
Liabilities
19128000
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
6679000
CY2013Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
1570000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
82627000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
97274000
CY2013Q4 us-gaap Goodwill
Goodwill
1585000
CY2013Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
38663000
CY2013Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
320000
CY2013Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
457000
CY2013Q4 us-gaap Assets
Assets
140838000
CY2013Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
128224000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10186000
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3155000
CY2013Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1870000
CY2013Q4 us-gaap Other Assets
OtherAssets
40000
CY2013Q4 us-gaap Other Assets Current
OtherAssetsCurrent
191000
CY2013Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
338000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1406000
CY2013Q4 sgmo Escrow Liability
EscrowLiability
275000
CY2014Q1 sgmo Number Of Research Program
NumberOfResearchProgram
2 Program
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
53377000 shares
CY2013Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8018000
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-6885000
CY2013Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
68000
CY2013Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000
CY2013Q1 us-gaap Proceeds From Sale Of Held To Maturity Securities
ProceedsFromSaleOfHeldToMaturitySecurities
12910000
CY2013Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1339000
CY2013Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3308000
CY2013Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2247000
CY2013Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-560000
CY2013Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-1480000
CY2013Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1329000
CY2013Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-9502000
CY2013Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3731000
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8220000
CY2013Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2247000
CY2013Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
147000
CY2013Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1329000
CY2013Q1 us-gaap Operating Expenses
OperatingExpenses
11528000
CY2013Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
231000
CY2013Q1 sgmo Collaboration Agreements
CollaborationAgreements
4083000
CY2014Q1 dei Trading Symbol
TradingSymbol
SGMO
CY2014Q1 dei Entity Registrant Name
EntityRegistrantName
SANGAMO BIOSCIENCES INC
CY2014Q1 dei Amendment Flag
AmendmentFlag
false
CY2014Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2014Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014Q1 dei Document Type
DocumentType
10-Q
CY2014Q1 dei Document Period End Date
DocumentPeriodEndDate
2014-03-31
CY2014Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001001233
CY2014Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
63199000 shares
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
11379000
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
CY2014Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
50000
CY2014Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7302366 shares
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
15727000
CY2014Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1723000
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3644000
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
101371000
CY2014Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
50000
CY2014Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
18888000
CY2014Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
295000
CY2014Q1 sgmo Collaboration Agreements
CollaborationAgreements
7568000
CY2014Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"> <b><i>Use of Estimates and Classifications</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value measurements, business combinations including the fair value of the contingent consideration liability for payments to former Ceregene Inc. (Ceregene) stockholders and intangible assets related to the acquisition of Ceregene, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</p> </div>
CY2014Q1 us-gaap Revenues
Revenues
8116000
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
71000
CY2014Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7563000
CY2014Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
16773000
CY2014Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
39000
CY2014Q1 us-gaap Revenue From Grants
RevenueFromGrants
548000
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7611000
CY2014Q1 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
45000
CY2014Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2205000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-7572000
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
126000
CY2014Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
9000
CY2014Q1 us-gaap Proceeds From Sale Of Held To Maturity Securities
ProceedsFromSaleOfHeldToMaturitySecurities
20786000
CY2014Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
1732000
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1907000
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
116637000
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3887000
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12033000
CY2014Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
7585000
CY2014Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
123000
CY2014Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1907000
CY2014Q1 sgmo Proceeds From Issuance Initial Public Offering Net Of Costs
ProceedsFromIssuanceInitialPublicOfferingNetOfCosts
93786000
CY2014Q1 sgmo Potential Royalty Payments To Entity
PotentialRoyaltyPaymentsToEntity
Two times the amount Sangamo receives in funding under the agreement

Files In Submission

Name View Source Status
0001193125-14-187386-index-headers.html Edgar Link pending
0001193125-14-187386-index.html Edgar Link pending
0001193125-14-187386.txt Edgar Link pending
0001193125-14-187386-xbrl.zip Edgar Link pending
d699448d10q.htm Edgar Link pending
d699448dex101.htm Edgar Link pending
d699448dex102.htm Edgar Link pending
d699448dex103.htm Edgar Link pending
d699448dex311.htm Edgar Link pending
d699448dex312.htm Edgar Link pending
d699448dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sgmo-20140331.xml Edgar Link completed
sgmo-20140331.xsd Edgar Link pending
sgmo-20140331_cal.xml Edgar Link unprocessable
sgmo-20140331_def.xml Edgar Link unprocessable
sgmo-20140331_lab.xml Edgar Link unprocessable
sgmo-20140331_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending